US · NAOV
NanoVibronix, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Elmsford, NY 10523
- Website
- nanovibronix.com
Price · as of 2024-12-31
—
Market cap 3.86M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $1,416.94 | — |
| Intrinsic Value(DCF) | $15.75 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $10,780.00 | $5,710.30 | $0.00 | $0.00 | $2,979.89 |
| 2016 | $13,640.00 | $5,508.29 | $24.67 | $0.00 | $0.00 |
| 2017 | $10,120.00 | $6,414.70 | $205.18 | $0.00 | $0.00 |
| 2018 | $9,020.00 | $4,474.04 | $0.38 | $0.00 | $0.00 |
| 2019 | $6,006.00 | $2,753.32 | $233.60 | $0.00 | $0.00 |
| 2020 | $2,486.00 | $3,705.03 | $14,421.17 | $0.00 | $0.00 |
| 2021 | $1,674.20 | $1,399.98 | $1,590,605.35 | $0.00 | $0.00 |
| 2022 | $387.20 | $409.61 | $88.25 | $0.00 | $1,728.88 |
| 2023 | $100.21 | $3,474.07 | $521,190.95 | $0.00 | $0.00 |
| 2024 | $39.38 | $1,416.94 | $6,967.56 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates NanoVibronix, Inc.'s (NAOV) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $1,416.94
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$15.75
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NAOV | NanoVibronix, Inc. | $4.84 | 3.86M | +29,176% | +225% | — | — | -2.87 | 16.95 | 4.15 | -2.71 | — | 16.95 | 58.95% | -140.03% | -144.84% | -160.56% | -1021.97% | -71.92% | 0.19 | -26.53 | 1.22 | 0.37 | 0.17 | -3524.00% | 1205.00% | -3009.00% | -23.70% | -0.92 | -718.69% | 0.00% | 0.00% | 0.00% | -2.79 | -3.97 | 3.91 | -27.16 |
| ACON | Aclarion, Inc. | $7.50 | 4.37M | +420,393% | +99% | — | +2,922,798% | -0.01 | 0.04 | 0.77 | 0.07 | — | -0.11 | -183.81% | -12057.23% | -15293.78% | -5777.80% | 10310.16% | -305.15% | 0.00 | -10.30 | 0.71 | 0.41 | 0.07 | -9062.00% | -3936.00% | 4851.00% | -15922.34% | -4.57 | 10460.70% | 0.00% | 0.00% | 1589.28% | 0.08 | 0.07 | -9.15 | -42.51 |
| AMIX | Autonomix Medical, Inc. C… | $0.84 | 4.3M | — | — | — | — | -0.23 | 0.32 | — | 0.59 | — | 0.32 | 0.00% | — | — | -145.10% | 2283.35% | -118.77% | 0.00 | -65.84 | 5.63 | 5.35 | 0.83 | -6937.00% | — | 2407.00% | -316.49% | -4.84 | 1629.95% | 0.00% | 0.00% | 58.54% | 0.56 | 0.79 | — | -9.21 |
| BBLG | Bone Biologics Corporatio… | $2.01 | 3.61M | — | — | — | — | -1.86 | 2.19 | — | 40.32 | — | 2.19 | 0.00% | — | — | -128.71% | -22020.98% | -108.23% | 0.00 | — | 10.22 | 8.80 | -31.03 | -8580.00% | — | -5683.00% | -53.95% | -10.92 | -21530.04% | 42.02% | -78.10% | 45.92% | -1.02 | -1.05 | — | -21.20 |
| BJDX | Bluejay Diagnostics, Inc. | $1.73 | 2.58M | — | — | — | — | -0.10 | 0.13 | — | 0.49 | -0.17 | 0.13 | 0.00% | — | — | -178.98% | -533.23% | -133.92% | 0.04 | -8.71 | 6.05 | 5.33 | 0.61 | 5724.00% | — | -989.00% | -1057.58% | -9.65 | -604.40% | 0.00% | 0.00% | 289.45% | 0.46 | 0.41 | — | -9.61 |
| CNSP | CNS Pharmaceuticals, Inc. | $6.82 | 3.92M | — | — | — | — | -0.68 | 1.63 | — | -0.27 | — | 1.63 | 0.00% | — | — | -1703.39% | 642.50% | -285.68% | 0.05 | -924.50 | 3.43 | 2.91 | 0.41 | -3522.00% | — | 2102.00% | -169.67% | -6.78 | 738.03% | 0.00% | 0.00% | 58.36% | -0.27 | -0.23 | — | -15.99 |
| GRI | GRI Bio, Inc. | $1.68 | 4.23M | +10,214% | — | — | — | -0.02 | 0.04 | — | 0.66 | — | 0.04 | 0.00% | — | — | -238.17% | 791.34% | -166.00% | 0.01 | — | 3.25 | 3.11 | 0.68 | -9212.00% | -10000.00% | 1833.00% | -4086.53% | -3.85 | 673.21% | 0.00% | 0.00% | 1303.49% | 0.66 | 0.78 | — | -12.03 |
| HSCS | HeartSciences Inc. | $2.90 | 6.52M | +667% | -43% | — | +20,854% | -0.45 | 19.02 | 897.28 | -0.71 | — | -2.77 | -2884.71% | -192013.13% | -201499.52% | -233.04% | -360.16% | -127.72% | 14.55 | -16.69 | 0.59 | 0.30 | -0.23 | -5016.00% | -7661.00% | 2014.00% | -190.70% | -2.00 | -320.95% | 0.00% | 0.00% | 0.00% | -0.69 | -0.78 | 1331.10 | -31.62 |
| MOVE | Movano Inc. | $5.30 | 3.79M | — | — | — | — | -90.32 | 291.38 | 2115.60 | -88.77 | — | 291.38 | -196.84% | -2391.12% | -2342.25% | -439.23% | 1722.15% | -228.79% | 0.03 | — | 3.02 | 2.31 | 0.32 | -3810.00% | — | -1410.00% | -1.05% | -6.54 | 1602.63% | 0.00% | 0.00% | 0.08% | -88.16 | -94.73 | 2107.98 | 299.75 |
| NDRA | ENDRA Life Sciences Inc. | $5.21 | 3.92M | — | — | — | — | -0.34 | 1.54 | — | -0.12 | -0.46 | 1.54 | 0.00% | — | — | -280.02% | -690.14% | -205.38% | 0.23 | — | 5.67 | 5.34 | 0.25 | 7402.00% | — | -2260.00% | -188.25% | -12.23 | -473.18% | 0.13% | 0.00% | 5.35% | -0.12 | -0.17 | — | -38.53 |
| VERO | Venus Concept Inc. | $2.11 | 3.92M | +5,399% | -43% | — | +19,432% | -0.05 | 0.91 | 0.03 | -1.14 | -0.01 | -0.83 | 68.34% | -41.93% | -72.49% | 806.37% | -52.93% | -58.05% | 18.16 | -3.55 | 1.60 | 0.78 | -1.08 | 86901.00% | -1509.00% | -1376.00% | -520.15% | -0.37 | -22.07% | 0.00% | 0.00% | 1652.41% | -1.50 | -3.66 | 0.63 | -6.37 |
About NanoVibronix, Inc.
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
- CEO
- Brian M. Murphy
- Employees
- 31
- Beta
- 2.05
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($15.75 ÷ —) − 1 = — (DCF, example).